Navigation Links
BZL101 in Medical News

Bionovo to Present at Wall Street Analyst Forum's 20th Annual Institutional Investor Conference

...d or currently on the market. bzl101 and other Cancer Drug Candidates ...the powerful and selective mechanism of action for bzl101 in cancer tumors. Another study was presen...8. Results from a second clinical study of bzl101 in advanced breast cancer was presented at ASCO, i...

Bionovo Announces Presentation at the National Cancer Institute

...o be leaders in their markets. Bionovo's clinical pipeline of drug candidates includes Menerba (MF101) for the treatment of menopausal hot flashes and bzl101 for the treatment of advanced breast cancer. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the s...

Bionovo Announces Cost Control Measures Taken

...o be leaders in their markets. Bionovo's clinical pipeline of drug candidates includes Menerba (MF101) for the treatment of menopausal hot flashes and bzl101 for the treatment of advanced breast cancer. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the s...

Bionovo Announces 2007 Financial Results and Highlights

...er Research (AACR). The presentation described how bzl101 elicits its cytotoxic activity on cancer cel... patients into a Phase 1/2 clinical trial of bzl101 for the treatment of advanced breast cancer, after presenting positive Phase 1 findings of bzl101 at the American Association of Cancer Resear...
BZL101 in Medical Technology

Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology

EMERYVILLE, Calif., Nov. 20 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI ) announced the company will present results from the Phase 1B clinical trial of their lead drug candidate for advanced metastatic breast cancer, BZL101, at the Society for Integrative Oncology's Fifth Internationa...

Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer

EMERYVILLE, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI ) announced today that its drug candidate for metastatic breast cancer, BZL101, will advance to Phase 2 clinical testing after the successful completion of a second Phase 1 clinical trial. The Phase 1B clinical...

Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles

- Results Presented at American Society of Clinical Oncology 44TH Annual Meeting - EMERYVILLE, Calif., June 2 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI ) today announced results from a second ongoing clinical trial of BZL101, an oral drug candidate, in...

Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101

BZL101 selectively kills cancer cells but not normal cells EMERYVILLE, Calif., April 1 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI ) today announced the publication of a peer-reviewed article in the journal Cancer Biology and Therapy that elucidates the molecular mechanisms un...

Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial

...es of its innovative breast cancer drug candidate, bzl101 were well tolerated. As a result, the company will... available efficacy information." About BZL101 bzl101 is an oral drug designed for the treatment of adva...argely on glycolysis (>85%) for energy production. bzl101 leads to energy collapse in cancer cells by inhibi...

Bionovo to Present Recent Findings of BZL101, Its Anti-cancer Agent, at the American Association of Cancer Research

... for cancer cell apoptosis (cell death) induced by bzl101 while leaving normal cells unaffected. As explaine...ctor of Cancer Research at Bionovo, the ability of bzl101 to induce apoptosis is due to attenuation of mitoc... of life conditions associated with menopause, and bzl101 is in Phase 1/2 for the treatment of advanced brea...

Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in Phase 2 Trial

...men's health. The company has two drugs in clinical testing. MF101 has completed Phase 2 for quality of life conditions associated with menopause, and bzl101 is in Phase 1/2 for the treatment of advanced breast cancer. The company has an additional pipeline of drugs in development for breast cancer, pancrea...
BZL101 in Biological Technology

Bionovo Announces 2008 Highlights and Year-End Financial Results

...d or currently on the market. bzl101 and other Cancer Drug Candidates ...the powerful and selective mechanism of action for bzl101 in cancer tumors. Another study was presen...8. Results from a second clinical study of bzl101 in advanced breast cancer was presented at ASCO, i...

Bionovo Reports Third Quarter 2008 Financial Results

... of advanced breast cancer, menopausal hot flashes, and menopausal vaginal atrophy. Recent advances have included: -- The Phase 1 portion of the bzl101 Phase 1/2 clinical trial for advanced metastatic breast cancer has now been completed successfully, showing positive safety and tolerabil...

Bionovo Reports Second Quarter 2008 Financial Results

...rence of $4.6 million. Company Highlights -- The Phase 1 portion of the bzl101 Phase 1/2 clinical trial for advanced metastatic breast cancer continues su...al trials for both MF101 and VG101." "We are very excited at the progress bzl101 is making in the clinical trials for advanced breast cancer. This drug cand...

Bionovo Reports First Quarter 2008 Financial Results

...th $33.3 million, a difference of $3.9 million. Company Highlights -- Patient enrollment and dosing continues in the Phase 1 portion of the bzl101 Phase 1/2 clinical trial for advanced metastatic breast cancer. Presentations, papers and scientific discussions have expounded the mechanis...

Bionovo Announces Third Quarter 2007 Financial Results

...dosing continues in the Phase 1 portion of the bzl101 Phase 1/2 clinical trial for advanced metastatic breast cancer. -- Bionovo presented data on bzl101 at the AACR-NCI-EORTC International Conference...r Targets and Cancer Therapeutics showing that bzl101 selectively elicits its cytotoxic activity on canc...
Other Tags
(Date:7/28/2014)... researchers in Taiwan has developed a new optical technology ... of diabetes sooner, when it is more easily treated. ... trials, it may pave the way for the early ... diabetic autonomic neuropathy, which is common among people with ... progressively affects the autonomic nerves controlling vital organs like ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Top Northridge ... coupon for new patients. Finding a new dentist can be ... dental issues that have gone untreated and worry about how ... Ariz specializes in patients with special concerns and dental needs ... comfortable and right at home. This special coupon can help ...
(Date:7/28/2014)... July 28, 2014 "I injured my shoulder ... said an inventor from Sunnyvale, Calif. "When I slept in ... the market are cumbersome and require too many straps. That ... developed the Multiple Functioning Vest to improve the design of ... so that they heal properly. This helps to speed up ...
(Date:7/28/2014)... HealthDay Reporter FRIDAY, July ... health insurance this year will face fines of up to ... the Internal Revenue Service says. The Obama administration on ... that some Americans will owe for failing to have health ... monthly national average premium for a bronze-level health plan. ...
(Date:7/28/2014)... 2014 Glidewell Laboratories announced today that ... successfully passed the five-year mark in clinical usage, and ... units prescribed by US dentists. , Even as BruxZir ... good results from respected clinical studies, many dentists expressed ... over extended years of clinical service before they would ...
Breaking Medicine News(10 mins):Health News:Wearable device for the early detection of common diabetes-related neurological condition 2Health News:Northridge Dentist, Dr. Farshid Ariz, is Now Offering a $100 Coupon for New Patients 2Health News:IRS Caps Fines on Uninsured Americans at $12K for Family of 5 2Health News:BruxZir® Solid Zirconia Surpasses Five Years of Clinical Use 2
(Date:7/27/2014)... like bacteria and fungi can evade treatment by acquiring ... drugs. These permanent mutations were once thought to be ... a new study has shown that microorganisms can use ... epimutations -- to gain the benefits of drug resistance ... discovered in a fungus called Mucor circinelloides, it is ...
(Date:7/27/2014)... computer cannot always find the solution a user wants. ... of computers that analyze a massive data set together. ... to present you with targeted ads, and how Amazon ... But big data is about more than just marketing. ... generating unprecedented quantities of information. That data may hold ...
(Date:7/25/2014)... on the land now called California, and many of ... plants they used for food, fuel, tools, and ritual. ... habitat and natural resources. , Frank Lake, an ecologist ... lead a field trip to the Stone ... America,s 99th Annual Meeting, in Sacramento, Cal. this August. ...
Breaking Biology News(10 mins):Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3New tools help neuroscientists analyze 'big data' 2New tools help neuroscientists analyze 'big data' 3New tools help neuroscientists analyze 'big data' 4New tools help neuroscientists analyze 'big data' 5Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3
Other Contents